6 patents currently held
151 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Oct 2037. from the record
Of the 151 now held by other companies, 49 were conveyed to Janssen Pharmaceutica N.V. in the filing they arrived in, and 102 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2037
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2039 · High confidence
Also notable
Ends Feb 2038 · High confidence
Also notable
Ends Oct 2037 · Medium confidence
Exo-Aza Spiro Inhibitors of Menin-Mll Interaction
US 11,396,517
The newest of the three, granted 2022. It anchors the portfolio to 2039, later than anything else here.
Cancer Treatment
US 11,077,106
Granted 2021. Computed term ends 2038.
Immunoglobulins and Uses Thereof
US 10,787,495
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2037. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Dec 2036 · High confidence
The most cited patent in this portfolio, cited by 57 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036.
now held by Genentech, Inc.
Also notable
Ends Nov 2035 · High confidence
Cited by 25 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Genentech, Inc.
Also notable
Ends Dec 2035 · High confidence
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Genentech, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 9 of the patents on this record were granted since Aug 16, 2026
- 3 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Multimodal System and Method for Predicting Cancer | 1 in force | to Nov 2042 |
| Overcoming Data Missingness for Improving Predictions | 1 in force | to Jul 2042 |
| Cap for an Injection Device | 1 in force | to Jan 2041 |
| Exo-Aza Spiro Inhibitors of Menin-Mll Interaction | 1 in force | to Jan 2039 |
| Cancer Treatment | 1 in force | to Feb 2038 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,787,495 | Immunoglobulins and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,077,106 | Cancer Treatment held by Janssen Pharmaceutica N.V. In force · High confidence | In force | High confidence | |
| US 11,396,517 | Exo-Aza Spiro Inhibitors of Menin-Mll Interaction held by Janssen Pharmaceutica N.V. In force · High confidence | In force | High confidence | |
| US 12,708,717 | Cap for an Injection Device In force · High confidence | In force | High confidence | |
| US 12,198,025 | Overcoming Data Missingness for Improving Predictions In force · High confidence | In force | High confidence | |
| US 12,665,089 | Multimodal System and Method for Predicting Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 151 patents in force now held by others · 12 patents ended · 230 applications pending · 102 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.